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Abstract
Prostate cancer is the most commonly diagnosed cancer in men all over the world. 
Localized cancers in the early stages can be well managed by surgical or radiation ther-
apy. Metastatic prostate cancer is treated with androgen deprivation therapy because 
androgen signaling is essential to the prostate tumor growth and anti-apoptotic ability. 
However, resistance develops quickly in the clinical course and leads to castration-resis-
tant prostate cancer (CRPC). Androgen receptor (AR) functions as a nuclear receptor to 
facilitate ligand-dependent transcriptional activation in the nucleus. AR interacts with 
several tissue-specific transcription factors such as forkhead box protein A1 (FOXA1) and 
regulates epigenetic status by recruiting epigenetic factors. In addition, AR transcriptional 
activity is modulated by interacting directly or indirectly with non-coding RNAs such as 
long non-coding RNAs (lncRNAs) and micro RNAs (miRNAs). Notably, enhanced AR 
signaling in CRPC has been documented in several studies; however, which of these 
factors are important for the biological function it remains poorly understood. Here, I 
review our current knowledge of the mechanistic roles of AR involved in prostate cancer 
progression and discuss the importance of the prostate cancer-associated signals.
Keywords: androgen receptor, prostate cancer, non-coding RNA, transcription, 
epigenetic
1. Introduction
Released hormone to an entire body is responsible for the development of various human diseases 
and physiology. Androgens, male sex hormones, mediate their effects predominantly by bind-
ing to the androgen receptor (AR), a member of the ligand-dependent nuclear receptor super-
family. Two major androgens, testosterone and dihydrotestosterone (DHT), bind and activate 
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AR to regulate target gene expression [1]. Testosterone produced in the testes is the most abun-
dant androgen. After diffusing into cells, testosterone is converted to dihydrotestosterone (DHT) 
by the enzyme 5α-reductase [2]. DHT directly binds to and activates AR even more tightly than 
testosterone [3]. Androgens play a key role in the development of the male genital tract favoring 
differentiation and external genitalia during fetal life and sexual characteristic during puberty 
and are required for the establishment of adult sexual function. In addition to the classical activi-
ties in the male reproductive system, androgens also have anabolic functions in other tissues 
such as bone, muscle and central nervous systems [4]. Notably, AR has a central role in prostate 
cancer progression. In this review, we focus on AR functions through epigenetic factors and 
non-coding RNAs that have been shown to play a role in prostate cancer progression.
2. De-regulation of AR during the progression of prostate cancer
AR is a member of the nuclear receptor superfamily [5] and plays a key role in androgen signaling 
(Figure 1A). In the absence of ligand, AR is expressed mainly in the cytoplasm forming a complex 
with molecular chaperones and co-chaperones from the heat shock protein (Hsp) family. Upon 
androgen treatment, a conformational change in the complex leads to nuclear translocation of 
AR. In the nucleus, AR binds as a dimer to specific DNA sequences called androgen respon-
sive elements (AREs), which are found in the vicinity of AR target genes [6]. AR activates gene 
expressions by modifying the epigenetic condition of AR binding regions [7]. Generally, nuclear 
receptors including AR have multiple domains called DNA binding domain, a ligand-binding 
domain (LBD), and an N-terminal domain (NTD), [2, 8, 9]. In the NTD, the transcriptional activa-
tion function 1 (AF1) domain promotes transcriptional activation with or without ligand bind-
ing [10], which is associated with enhanced AR function. AF2 domain in the LBD interacts with 
co-regulators with LXXLL motif [3]. Point mutations mapped to the LBD have been identified 
to have relevance with the treatment-resistance to drugs targeting AR in prostate cancer [11, 12].
Prostate cancer is one of the leading causes of cancer morbidity and mortality in developed 
countries. Androgens induce proliferation of prostate epithelial cells or prostate cancer tumor 
growth [13]. Early diagnosis of prostate cancer is currently based on the measurement of 
serum prostate-specific antigen (PSA), a representative AR target gene. Treatment of localized 
prostate cancer is determined based on clinico-pathological factors such as Gleason score, 
initial PSA level, patient’s age and clinical tumor stage [14]. Because AR and its downstream 
signaling are essential for the development and progression of both localized and advanced 
metastatic prostate cancer, hormone therapy is a first-line and initially successful strategy for 
treating advanced prostate cancer. Androgen deprivation therapy decreases the circulating 
testosterone levels to a very low amount, a condition called chemical castration of men [15].
However, most of these tumors relapse and progress to hormone therapy resistant prostate 
cancer (HRPC) or castration-resistant prostate cancer (CRPC). To overcome CRPC/HRPC, new 
AR inhibitors have been developed. Abiraterone acetate, a potent inhibitor of CYP17 reduces 
testosterone synthesis from cholesterol [16]. Despite suppression of circulating testosterone, 
castration does not decrease androgens enough from the prostate tumor microenvironment 
and residual androgen levels are well within the range capable of activating AR. Accordingly, 
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therapeutic strategies effectively targeting production of intratumoral androgens are necessary. 
Clinical studies showed that abiraterone improved overall survival, progression free survival, 
delayed initiation of chemotherapy and doubled the time to first skeletal event. Enzalutamide 
(MDV3100) is another novel endocrine treatment with reported significant anti-tumor activ-
ity [17]. It is an AR-receptor-signaling inhibitor, blocking nuclear translocation, DNA binding, 
and co-activator recruitment. Enzalutamide significantly prolonged the survival of men with 
metastatic CRPC after chemotherapy [18]. Although these new types of drugs bring impressive 
results, the duration of response is variable, and a majority eventually progress with a rising 
PSA. While the mechanisms determining resistance have not been fully elucidated, persistent 
AR activation provides a compelling rationale for developing more strategies to inhibit AR [19].
Figure 1. Epigenetic regulation of AR binding regions. (A) Androgen receptor (AR) translocates into the nucleus. By 
collaborating with FOXA1, AR is recruited to specific loci called androgen responsive elements (AREs) to activate its 
target genes. (B) Upon androgen treatment, several histone modifying enzymes were recruited to AR binding sites. 
PKCβ1-mediated histone H3T6 phosphorylation directs LSD1 for not H3K4 but H3K9 demethylation by cooperating 
with JMJ2D. H3T11 phosphorylation also accelerates WDR5-mediated MLL recruitments and LSD1 activity. MLL 
complex interacts with AR through menin and promotes histone H3K4 methylation to enhance AR dependent gene 
expression. SRC family and CTBP1/2 are AR interacting cofactors for histone acetylation or deacetylation.
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Enhanced AR downstream signals are caused by AR gene amplification, point mutation, AR 
variants (particularly AR-Vs), hypersensitivity to androgens, or intratumoral steroidogen-
esis [20–23]. AR mRNA is alternatively spliced to AR-Vs and results in prematurely termina-
tion of the full AR protein. Most AR-Vs are missing LBD, however, retain the NTD to drive 
transcription androgen-independently. Among these variants, AR-V7 is expressed in HRPC/
CRPCs most frequently and could be the therapeutic target of tumors resistant to existing 
therapies directed to androgen/AR [24, 25]. In addition, elevated AR expression increased the 
reactivity of prostate cancer cells to castrate levels of androgens and promotes resistance to 
AR-targeting drugs. Increased AR expression in CRPC is often mediated by AR gene amplifi-
cation. Thus, it is critical to investigate AR downstream-signaling or regulatory mechanisms 
by AR to understand how CRPC develop among the patients.
3. Investigation of AR-regulators and target genes
Chromatin immunoprecipitation (ChIP) and sequencing studies have revealed locations of 
AR bindings have been found in prostate cancer cells [26–28]. AR target genes such as ADP-
ribosylation factor GTPase-activating protein 3 (ARFGAP3) [29], Amyloid Beta Precursor Protein 
(APP) [30], Acyl-CoA Synthetase Long Chain Family Member 3 (ACSL3) [31], claudin-8 [32] 
and Transforming acidic coiled-coil-containing protein 2 (TACC2) [33], which promotes tumor 
growth by regulating cell cycle, intratumoral steroidogenesis, cell structure, have been identified 
in my research. Calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2) is overex-
pressed in prostate cancer and regulates cancer cell growth via its unexpected role as a hormone-
dependent modulator of anabolic metabolism, contributing to prostate cancer progression [26]. 
Ubiquitin-conjugating enzyme E2 C (UBE2C) was identified to be a CRPC-specific AR target 
gene and promoted G2/M mitotic cell division in prostate cancer cells [27]. Interestingly, andro-
gen regulates p53 localization by inducing GTPase-activating protein-binding protein 2 (G3BP2), 
which is an AR target gene [34]. G3BP2 associates with p53 and SUMO E3 ligase RAN bind-
ing protein 2 (RanBP2), promoting p53 nuclear export via increased p53 sumoylation. Elevated 
G3BP2 expression repressed docetaxel-mediated apoptosis and promoted CRPC tumor growth.
3.1. Epigenetic factors
In prostate cancer, deregulation of AR interaction with its coregulators within nucleus is com-
mon and activation of coregulators is frequently observed. AR has a role in the ligand-depen-
dent epigenetic changes by interacting with various coregulators such as histone-modifying 
enzymes. DNA, histones and other proteins formed chromatin as a highly ordered structure. 
Chromatin forms a unit called the nucleosome consisting of a histone octamer (H2A, H2B, 
H3 and H4, two pairs of each) and DNA. Both DNA methylation and histone modification 
patterns have also been investigated in prostate cancer. Histone modifications affect the inter-
action of DNA with histones, transcription factors or other proteins binding to DNA, thus 
playing a role in the epigenetic control of biological events. Lysine, arginine, serine and threo-
nine residues enriched in N-terminal histone tails serve as substrates for post-translational 
modifications such as acetylation, phosphorylation, methylation, ubiquitination, sumoylation 
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and deamination. Histone H3, one of the major histones, is most representative for epigenetic 
regulation. The methylation of lysine on position 9 (H3K9) and H3K27 is an epigenetic mark 
of condensed chromatin and silent loci. The methylation of H3K4 and H3K36 is associated 
with open chromatin structures. Acetylation of lysine residues of H3 is also correlated with 
enhanced enhancer/promoter activation. [5].
In a recent report, the potential for BET bromodomain protein inhibitors as a novel epigenetic 
approach to treatment of CRPC has been shown [35]. In prostate cancer cell lines, BET bromo-
domain inhibitor, JQ1, was demonstrated to induce apoptosis and down-regulate AR target 
gene expression. Bromodomain and the extra-terminal (BET) subfamily of human bromodo-
main proteins (BRDs), with a focus on BRD4, were found to play a major role in AR signaling 
and interact with AR via bromodomain 1/2. JQ1 inhibits this BRD4-AR bond, resulting in 
removal of RNA polymerase II from AR target genes [35]. This study suggests for the first 
time that modulating epigenetic function of AR could be a useful strategy to overcome clinical 
problems associated with AR signals.
Histone acetylation loosens the nucleosome packing within chromatin to increase DNA acces-
sibility, resulting in the recruitment of chromatin remodeling factors that lead to enhanced 
transcriptional activity. The BRD has the ability to recognize acetylated lysine residues [36]. 
This activity allows BRDs to play a vital role in histone acetylation-mediated gene transcrip-
tional regulation in chromatin. Such BRDs included Tripartite motif containing 24 (TRIM24), 
which interacts with AR and are highly expressed in CRPC [37]. Other studies revealed that 
E3 ubiquitin ligase substrate binding adaptor speckle-type POZ protein (SPOP) binds to and 
induces ubiquitination of BRD4 for degradation. In many prostate cancer tissues, SPOP is the 
most frequently mutated to enhance the expression level of BRD4 [38].
AR regulates the histone modifications in AR binding sites (ARBSs) and promotes enhancer 
activity by directly interacting with many co-regulators including steroid receptor coactivators 
(SRCs) or other histone-modifying enzymes [6, 39] (Figure 1B). Methylations of H3K4 (mono-, 
di- or tri-methylation) indicate the active promoter/enhancer regions [40] and promoted by 
the SET1/MLL histone methyltransferase (HMTase) complex. Menin protein binding to the 
N-terminus of MLL is important for MLL target gene expressions. Menin directly binds to AR 
and recruited MLL complex. Menin is highly expressed in CRPC tissues and associated with 
castration-resistant tumor growth [41]. Importantly, small molecule inhibitors against menin-
MLL interaction could be the new useful drugs for CRPC. MLL complex plays an important 
role for androgen-mediated gene induction and its activity is regulated finely. After androgen 
stimulation, protein kinase C-related kinase 1 (PRK1) promotes histone H3 threonine 11 phos-
phorylation (H3T11P) [42]. WD repeat containing protein 5 (WDR5), a subunit of the SET1/
MLL complex, associates with H3T11P and then promotes the recruitment of the MLL com-
plex for H3K4 tri-methylation (H3K4me3) in ARBSs [43]. WDR5 is a critical epigenetic integra-
tor and is overexpressed in prostate cancers. PRK1 kinase activity facilitates demethylation of 
H3K9 by cooperating with lysine-specific demethylase 1 (LSD1) [42, 44]. In addition, Protein 
kinase C beta 1 (PKCβ1) phosphorylates histone H3T6 to prevent lysine specific demethylase 
including LSD1 from histone H3K4 demethylation [45]. Moreover, C-terminal binding protein 
2 (CTBP2) is an androgen-responsive cofactor of AR. CTBP2 repressed tumor-suppressor genes 
and AR corepressors in prostate cancer cells, such as Nuclear receptor co-repressor (NCOR) 
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and receptor-interacting protein 140 (RIP140), by binding with AR to the promoter enhanc-
ers of these genes. Moreover, global gene-expression analyses revealed a positive effect on 
androgen-mediated gene expression, and CTBP2 silencing was found to increase AR interac-
tions with corepressors that limit histone modification [46]. Thus, these findings have a clinical 
relevance to develop new drugs for treatment by regulating epigenetic status [41].
Histone modification is also important for increased AR expression in CRPC [47]. Recent 
studies showed that both transcriptional and epigenetic changes are important for AR upreg-
ulation in prostate cancer. To introns of the AR gene, recruitments of AR and its associated 
cofactors such as LSD1, which represses transcription by inhibiting histone H3K4 methylation 
are induced by androgen. This feedback loop mechanism regulates AR expression negatively 
by androgen. Interestingly, after long-term incubation in castration level of androgens, AR 
expression increases in prostate cancer cells and then low levels of androgens can activate AR 
regulated genes in CRPC without repressing genes such as the AR itself.
3.2. Collaborative transcription factors
Functional ARBSs were not only determined by sequence motifs but also chromatin accessi-
bility. ChIP-sequence (ChIP-seq) analyses using next-generation sequencers have been devel-
oped as a high-throughput strategy to identify transcription factor binding regions [48]. For 
instance, AR ChIP-seq was performed in two LNCaP-derived prostate cancer cell lines with 
higher AR expression [49]. Interestingly, more ARBSs were obtained in these cell lines when 
they were treated with low concentrations of androgen. These data indicate that the higher 
expression of AR sensitizes the receptor binding to genome, thus illustrating the mechanism 
that the AR signaling pathway is enhanced in CRPC.
Furthermore, by analyzing enriched motifs around ARBSs, AR-associated transcription part-
ners such as forkhead box protein A1 (FOXA1) [50], ERG, GATA2 [51], Oct1 [31], RUNX1 [52] 
and NKX3–1 [50] have been mapped to the prostate cancer genome and these studies sug-
gested the global role of these factor to activate AR-driven transcriptional program. Among 
them, a chromatin-opening transcription factor, FOXA1, is able to directly bind to the chro-
matin to open up the local nucleosomal domain (Figure 1A). In prostate cells, FOXA1 protein 
has been shown physically interact with the AR protein and plays critical roles in regulating 
the transcription of prostate genes [7]. Moreover, ARBSs in CRPC tissues were found by ChIP-
seq and most of them could not been identified in cell lines. Many adjacent genes were in vivo 
restricted set of AR-regulated genes. Transcription factor motifs such as E2F, Myc and STAT 
were significantly enriched in these CRPC-specific ARBSs [53]. Another study revealed the 
colocalization of FOXA1 and homeobox B13 (HOXB13) at a set of ARBSs in human tumor 
tissues. These ARBSs were consistently reprogrammed for prostate tumor development [54].
4. The roles of non-coding RNAs in AR action and prostate cancer 
biology
Recent advances in DNA sequence technology have demonstrated that more than 90% of the 
human genome is actively transcribed. The encyclopedia of DNA elements (ENCODE) project 
Advances in Testosterone Action64
has shown that only 2% of these transcripts are translated into proteins [55]. The non-coding 
RNAs (ncRNAs), that occupy the majority of transcripts in the nucleus, were initially thought 
as the “dark matter.” Non-coding RNAs are broadly categorized into short and long transcripts. 
Short non-coding RNAs with a length within 200 nucleotides include such as transfer RNA, 
microRNA (miRNA), and snoRNA. miRNAs play important roles in cancer by post-transcrip-
tional modification of target mRNA or protein expression. Long non-coding RNAs (lncRNAs) 
represent most of the transcribed ncRNA in the human genome longer than 200 bp. GENCODE 
v27 includes 15,778 human lncRNA-related genes, which produce 27,908 lncRNAs [56].
4.1. lncRNA
LncRNAs exhibit similar structure and biogenesis as mRNAs. They are polyadenylated and 
may function in either nuclear or cytoplasmic compartments. Growing number of evidences 
have shown that lncRNAs are involved in numerous human diseases including cancer [57]. 
Global nuclear run-on sequencing (GRO-seq) was developed as a new technology to detect 
androgen-induced transcripts including lncRNAs [58]. This study has demonstrated that the 
production of enhancer-templated non-coding RNAs (eRNAs) is important for nucleosome 
remodeling to induce enhancer/promoter interaction by looping and gene activation. It was 
also shown that androgen promotes both transcriptional initiation and elongation. These 
active enhancers are tuned dynamically to modulate gene expression network in prostate can-
cer. AR is widely recruited to these eRNA-bound enhancer- promoter regions for activating 
the genes in the vicinity. Interestingly, knockdown of eRNA represses androgen-dependent 
enhancer promoter interaction and gene activation [59]. DNA nicking activity of topoisomer-
ase I (TOP1) was found to produce robust eRNA for enhancer activation. Furthermore, DNA 
damage repair machinery is recruited kinetically to the AR-regulated enhancers [60].
LncRNAs are able to fold into secondary and tertiary structures by which they perform their 
function (Figure 2A). Direct regulation of AR epigenetic function by lncRNA is strikingly 
receiving attention among all. Prostate cancer gene expression marker 1 (PCGEM1) was found as 
an androgen-regulated and prostate tissue-specific lncRNA [61]. Overexpression of PCGEM1 in 
prostate tumors were observed and associated with the anti-apoptotic activity by inhibiting p53 
and p21 induction [62]. Prostate cancer noncoding RNA 1 (PRNCR1) was identified by investigat-
ing the surrounding region of SNPs (single nucleotide polymorphisms) correlated with pros-
tate cancer susceptibility. Importantly, both PCGEM1 and PRNCR1 cooperatively functions for 
AR-mediated gene expression [63]. The association of PCGEM1 and PRNCR1 with AR was 
shown to be essential in the process of AR activation. Moreover, PCGEM1 was found to interact 
with pygopus homolog2 (Pygo2) and PRNCR1 with DOT1-like histone H3 methyltransferase 
(DOT1L). By modulating AR proteins with such interacted enzymes, these two lncRNAs were 
shown to be responsible for AR-associated loop formation between enhancer and promoter.
Another lncRNA, steroid receptor RNA activator (SRA) modulates the functions of various 
nuclear receptors, such as AR, estrogen receptor (ER), progesterone receptor (PR), glucocor-
ticoid receptor (GR) and thyroid hormone receptor (TR). SRA associates with a coactivator 
SRC-1 (steroid receptor coactivator) and six stem-loop motifs in SRA are required for co-acti-
vation. Interestingly, overexpression of SRA was found in various tumors including prostate 
cancer compared with normal tissues [64, 65].
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HOX Antisense Intergenic RNA (HOTAIR) is an lncRNA transcribed in the antisense direction 
from the HOXC gene cluster. HOTAIR associates with the polycomb repressive complex 2 
(PRC2) for acting as a transcriptional regulators in trans. PRC2 is recruited to the HOXD locus 
HOTAIR-dependently, leading to silenced transcription across a 40-kb region. Moreover, 
HOTAIR associates with LSD1/CoREST/REST complex. This interaction coupled PRC2 and 
LSD1 to induce histone H3K27 methylation and K4 demethylation for gene silencing [66]. 
Thus, lncRNAs interacts with chromatin remodeling complexes to promote heterochromatin 
formation in specific loci, resulting in target gene expression changes. In addition, HOTAIR 
expression is correlated with the disease progressions of breast and prostate cancer [67, 68]. 
HOTAIR high expressions in these cancers are correlated with poor prognosis. This finding 
reflects the regulation of steroid hormone function by HOTAIR. HOTAIR is negatively regu-
lated by androgen treatment and induced by depleting androgen. Mechanistically, HOTAIR 
blocks the association of E3-ubiquitine ligase MDM2 with AR by binding to AR. This binding 
inhibits ubiquitin-mediated degradation and stabilizes AR protein level to activate the AR 
mediated transcription for driving CRPC development [68].
Suppressor of cytokine signaling 2-antisense transcript 1 (SOCS2-AS1) was found in our direc-
tional RNA-seq and ChIP-seq analysis [69]. SOCS2-AS1 is highly expressed in castration-
resistant model cells and promotes cell proliferation and inhibits apoptosis induced by 
docetaxel. SOCS2-AS1 repressed apoptosis-related genes such as TNFSF10/TRAIL, which are 
AR target genes. For molecular mechanism in this gene regulation, SOCS2-AS1 is involved 
with AR activation by promoting the recruitments of coregulators to AR-occupied regions by 
interacting with AR (Figure 2A).
Figure 2. The role of non-coding RNA in AR-mediated transcription. (A) The role of enhancer RNA (eRNA) or other 
AR interacting lncRNAs. These lncRNAs (eRNA, PCGEM1, PRNCR1 or SRA) promotes loop formation for promoter/
enhancer interaction. HOTAIR enhances AR protein stability by inhibiting ubiquitylation of AR. SOCS2-AS1 regulates 
cofactor recruitments to AR. (B) Androgen-induced miRNA mediated TET2 repression inhibits 5-hmC modifications in 
FOXA1 occupied enhancer regions. By removal of 5-hmC, FOXA1 is activated and induce FOXA1 or ARregulated genes 
such as mTOR.
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Global transcriptome analysis showed that most of the genome can be transcribed from both 
sense and antisense strands. More than 1000 pairs of sense/antisense transcripts were obtained 
and antisense transcription is involved in such bidirectional gene regulation [70, 71]. Sense-
transcript is regulated by antisense through several mechanisms. For example, post-transcrip-
tional degradation is caused by antisense transcript. Another mechanism is recruitments of 
antisense RNA associated transcription factors for epigenetic regulation. In prostate cancer, 
an lncRNA, Prostate cancer antigen 3 (PCA3), was found to be an overexpressed in prostate can-
cer tissues. In 95% of the prostate tumors, the expression of PCA3 is upregulated compared 
with adjacent normal prostate tissues. PCA3 RNA levels can also be measured by urinary test 
more specifically than prostate specific antigen (PSA) measurement [72]. Therefore, it can be 
a helpful biomarker to diagnose prostate cancer [73]. AS an antisense transcript, PCA3 func-
tions as an oncogenic lncRNA by inhibiting its overlapped gene Prune Homolog 2 (PRUNE2), 
which is a tumor suppressor gene. PCA3 represses PRUNE2 expression by formation of a 
double-stranded RNA with PRUNE2 mRNA for reducing post transcriptionally [74].
Genome-wide androgen-regulated transcriptome analysis identified a new androgen-responsive 
lncRNA, CTBP1-AS [75]. C-terminal binding protein 1 (CTBP1) functions as a transcriptional 
repressor for AR and negatively regulates AR downstream signals. It was demonstrated 
that CTBP1-AS is regulated by AR-bindings to its promoter region. In addition, CTBP1-AS 
associates with a RNA binding protein, PSF (PTB-associated splicing factor) to transcription-
ally repress its target genes such as CTBP1 via histone deacetylation [75]. Then androgen- 
regulated lncRNAs mediates AR function by modulating epigenetic status and gene expres-
sion. Moreover, CTBP1-AS promotes prostate cancer cell cycle progression by repressing cell 
cycle regulators such as p53 and SMAD3 globally [75]. Thus, CTBP1-AS and PSF modulate 
global gene expression transcriptionally and post-transcriptionally to promote AR and pros-
tate cancer-associated signals. These findings suggest that targeting CTBP1-AS and PSF may 
represent a useful therapeutic strategy to overcome castration-resistance in prostate cancer.
Interestingly, another report has shown that PSF binds to another CRPC-associated lncRNA, 
Second Chromosome Locus Associated with Prostate 1 (SChLAP1) [76], and mRNAs of various 
AR target genes to enhance their stability. In CRPC model cells, pathway analysis showed 
that PSF primarily targets spliceosome genes for enhancing their expressions. Interestingly, 
in addition to PSF, these wide-range of spliceosome genes are overexpressed in metastatic 
prostate cancer tissues, suggesting the importance of splicing factors in the disease progres-
sion. PSF also binds to AR mRNA promoting AR splicing such as AR-V7 and expression 
[76] in CRPC. In addition to PSF, heterogeneous nuclear ribonucleoprotein L (HNRNPL) 
was identified by CRISPR/Cas9 knockout screen to be required for prostate cancer growth. 
HNRNPL also regulates the alternative splicing of a set of RNAs, including AR transcript [77]. 
Collectively, these recent studies revealed the novel roles of RNA processing factors in modu-
lation of AR splicing and expression. Aberrant expressions of splicing factors would induce 
the diversity of oncogenic gene expressions for promoting prostate cancer.
Growth arrest-specific 5 (GAS5) was originally identified as a gene that is preferentially expressed 
in growth arrested cells [78]. In prostate cancer cell lines, overexpression of GAS5 induced apop-
tosis [79] and cell cycle arrest via enhanced expression of p27, a tumor suppressor [80]. GAS5 
associates with steroid receptors including AR and forms a structure that blocks the DNA-
binding site of the steroid receptor, resulting in repression of steroid-mediated transcription [81].
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These analyses of lncRNA functions revealed a novel transcriptional regulatory mechanism. 
Several lncRNAs such as SRA and SOCS2-AS1 associate with AR protein and promote recruit-
ment of cofactors (Figure 2A). Other mechanisms contain loop forming between promoter and 
enhancer (eRNA, PCGEM1 and PRNCR1) or enhancing AR protein stability (HOTAIR) to acti-
vate AR action. Regulation of genes related with cancer development or cell cycle controls by 
interacting with RNA-binding transcriptional repressor (CTBP1-AS) would be another mech-
anism to promote cancer progression. Androgen-regulated lncRNAs (PCGEM1, HOTAIR, 
CTBP1-AS and SOCS2-AS1) have important roles in these gene expressions. Moreover, recent 
analyses have shown the importance of RNA-binding proteins (PSF/NONO, HNRNPL) in 
prostate cancer progression. Because only a limited number of lncRNA functions have been 
demonstrated, we should investigate molecular functions of more lncRNAs in tissue and spa-
tial specific manner in the future.
4.2. miRNA
MicroRNAs (miRNAs) are evolutionally conserved single-stranded small non-protein 
Generally miRNAs binds to the 3′ untranslated region (UTR) of mRNAs to inhibit their 
translation. For examples, dysregulation of miRNA expression profiles during the progres-
sion of prostate cancer have been discussed [82]. In these studies, miR-21, miR-29a/b, miR-32, 
miR-99a, miR-148a, miR-125b and miR-141 were found to be androgen-regulated miRNAs 
and dysregulated in prostate cancer. Upregulated miR-21 enhanced AR-dependent cell pro-
liferation and associated with development of CRPC [83, 84]. Another androgen regulated 
miRNA, miR-125b targets apoptosis inducing factors regulated by p53 (PUMA and BAK1) 
[85]. Thus, by repressing these genes, overexpression of miR-125b in tumors collapses the bal-
ance between pro- and anti-apoptotic processes. It was shown that miR-148a is also regulated 
by androgen and highly induced in AR positive prostate cancer cells. miR-148a targets cullin-
associated and neddylation dissociated 1 (CAND1), a cell cycle regulator, to promote cell pro-
liferation [86]. Moreover, miR-32 inhibits apoptosis by targeting BIM, a pro-apoptotic member 
of the BCL2 family [87]. Both miR-32 and miR-148a were overexpressed in CRPC tissues, indi-
cating that these miRNAs have important roles in the promotion of castration-resistance [87].
DNA methylation is also the representative epigenetic mark adding a methyl group to the 5′ 
position of cytosine (5-mC). DNA methylation is added or removed in a spatially and tem-
porally defined context throughout the genome including enhancer/promoter regions. DNA 
methyltransferases (DNMTs) contributes to the process as enzymes. DNMTs include DNMT3A/
DNMT3B for de novo and DNMT1 for maintenance of methylation. The ten-eleven translocation 
(TET) family proteins catalyzed the production of 5-hydroxymethylcytosine (5-hmC), an oxida-
tion product of 5-mC. Several studies have demonstrated that 5-hmC is not only an intermediate 
product of a demethylation process, but can also function as a stable epigenetic mark [88].
Interestingly, recent study has demonstrated that miR-29 family and miR-22 are highly 
induced by androgen in hormone-therapy resistant prostate cancer [89]. In prostate can-
cer clinical samples revealed that the expression level of miR-29a/b is negatively associated 
with that of TET2. Interestingly, in situ hybridization (ISH) study of clinical samples indi-
cated that miR-29a/b is highly expressed in a subset of prostate cancers with poor prognoses. 
Mechanistically, TET2 repression decreased 5-hmC levels, which is correlated with FOXA1 
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transcriptional activity. FOXA1 activation induced expressions of prostate cancer related 
genes. One of such 5-hmC regulated genes was mammalian target of rapamycin (mTOR) 
(Figure 2B). These experimental and clinical data suggested a novel oncogenic role of miR-29 
family in prostate cancer progression [89]. The roles of miR-29 family in cancer are still con-
troversial because their expressions are reduced in several cancer tissues in comparison with 
normal [90]. However, their overexpression inhibits apoptosis in lung cancer as oncogenic 
miRNAs [91]. Exome sequencing analysis revealed that somatic mutations of TET2 exon are 
involved in metastatic CRPC development [92]. Rare variation in TET2 is also associated with 
the development of prostate cancer [93]. TET2 could directly regulate AR-signaling by bind-
ing to AR [94]. Thus, the role of TET2 and 5-hmC-modification in prostate cancer deserves 
additional analysis and may define a subset of metastatic disease.
Studies of non-coding RNAs in AR signals are mainly reported in the research field of pros-
tate cancer. However, knockout of the miRNA processing enzyme, Dicer 1, Ribonuclease III 
(DICER), in mice inhibited AR function tissue specifically in muscle. In addition, castration 
in rats inhibited the expression of a large set of miRNAs in prostate and muscle, suggesting 
the importance of miRNAs in the physiological functions of androgens in other tissues [95].
5. Conclusion and perspective
The majority of prostate cancer and CRPC tumors are driven by AR signaling. AR-mediated 
resistance to hormone therapy can be acquired by multiple mechanisms. AR mutation, ampli-
fication and truncated variants have been identified to explain aberrant AR activation in pros-
tate cancer progression. AR coregulators and collaborating transcription factors are essentials 
for AR to exert its transcriptional activity. Recently the role of non-coding RNAs such as 
lncRNAs and miRNAs has been realized to play a critical role in AR activation and prostate 
cancer progression. Such alterations of AR function lead to positive or negative regulation 
of the growth and invasion ability of cancer cells. Although AR-targeting drugs have been 
developed, we could not eliminate CRPC due to the adaptive evolution of the disease during 
the treatment. Combinational therapies are required to overcome CRPC problems. Therefore, 
it is urgent to find better predictive biomarkers or therapeutic targets which have an efficacy 
for diagnosing and treating prostate cancer and CRPC.
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